Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II proof of concept trial of dCellVax in patients with metastatic breast cancer

Trial Profile

Phase I/II proof of concept trial of dCellVax in patients with metastatic breast cancer

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 02 Oct 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IDO-silenced dendritic cell vaccine Regen BioPharma (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Regen BioPharma
  • Most Recent Events

    • 14 Sep 2016 According to Regen BioPharma media release, the company has announced submission to the Food and Drug Administration (FDA) of a revised Investigational New Drug (IND) application.
    • 27 May 2015 According to a Regen BioPharma media release, the company is currently in the process of addressing FDA questions related to the submitted IND (IND #16200) before starting the clinical trial.
    • 09 Apr 2013 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top